Case report

**Splenectomy for solitary splenic metastasis of ovarian cancer**

Yang Seok Koh, Jung Chul Kim* and Chol Kyoon Cho

Address: Department of Surgery, Chonnam University Medical School, Chonnam National University Hospital, 8 Hak-dong, Dong-gu, Gwangju 501-757, Korea

Email: Yang Seok Koh - koh88@dreamwiz.com; Jung Chul Kim* - 3rdvivace@hanmail.net; Chol Kyoon Cho - ckcho@jnu.ac.kr

* Corresponding author

**Abstract**

**Background:** Splenic metastases occur in rare cases with a few case reports of patients in the literature. Generally, splenic metastases mean late dissemination of a disease. Solitary splenic metastases from solid tumors are extremely unusual.

**Case presentation:** We report a case of a patient with ovarian mucinous cystadenocarcinoma who underwent splenectomy for isolated parenchymal metastasis.

**Conclusion:** Ovarian epithelial tumors comprised most of isolated splenic metastases from gynecologic tumor. When isolated splenic recurrence is suspected on image studies and serum tumor markers, intraabdominal gross findings should be examined to exclude peritoneal carcinomatosis. If only spleen was under suspicion of recurrence of ovarian cancer, splenectomy may play a therapeutic role.

**Background**

Splenic metastases from solid tumors occur in late stage of a disease, so those can hardly be an indication for a surgery. Cancers of the ovaries, lung, breast, stomach, skin and colon are known to metastasize to the spleen [1]. Even though recent reports suggest increasing incidence of splenic metastasis from gynecologic tumors [2-8], the number of the cases that isolated splenic metastasis is fewer than 25 in the literature worldwide. Among them, solitary parenchymal metastasis would comprise the small portion. Fewer than 15 cases of splenic metastasis occur from the ovaries as a primary site, pathology revealed cystadenocarcinoma.

We present a case of mucinous cystadenocarcinoma that recurred in the splenic parenchyma.

**Case presentation**

A 29-year-old woman was admitted our hospital on August 1999, had been diagnosed as mucinous tumor of borderline malignancy a year ago. She was followed up at a local clinic. On the follow-up study, the patient's CEA level was raised to 43.32 U/L and CT scan showed splenomegaly with cystic lesion. Her past medical history was not significant. She already underwent two surgeries. The first surgery, right salpingo-oophorectomy, was performed after being diagnosed as dermoid cyst. She was healthy thereafter. Seven years later, left ovarian mass was found on the routine check. At the second surgery, left ovarian mass excision, mucinous tumor of borderline malignancy was diagnosed.

During follow-up after the second surgery, she was referred to our hospital on the suspicion of carcinomatosis peritonei. On the preoperative evaluation (Figure 1),
splenic lesion, which had been existed for 2 years, was merely noticed as simple cystic lesion unrelated to the ovarian mass.

To exclude peritoneal carcinomatosis, open laparotomy was performed. On opening the abdomen, no abnormal gross findings were found except the splenic lesion, which reported as probable metastatic adenocarcinoma on frozen sections. After splenectomy was carried out, peritoneal washings and multiple biopsies on the omentum, peritoneum, mesentery, and left ovary were performed to rule out possible microscopic peritoneal dissemination. Suspecting the transabdominal metastasis, 100 mg of cisplatin was infused into the peritoneal cavity at the end of the operation; however no intraperitoneal recurrence was confirmed after tissue diagnosis.

Final pathologic examination (Figure 2) showed metastatic mucinous cystadenocarcinoma. Peritoneal washings and multiple biopsies were all negative. The patient was recovered from the surgery without the evidence of sepsis of severe thrombocytosis. The patient received 5 courses of Taxol and Carboplatin as postoperative chemotherapy.

Two years after the surgery, 3 × 3-sized mass on the left ovary, which assumed to be recurrence, was detected. She has been followed up at outpatient department receiving symptomatic treatment and chemotherapy.

Discussion
The frequency of splenic metastasis has been reported 2.3 to 7.1 per cent from autopsy series of cancer patients [9-11]. Splenic metastases from the ovaries, uterus, uterine cervix, lung, breast, stomach, skin and colon have been reported, and ovarian cancer comprises the three fourth.

Until now, in the literature, splenic capsular metastasis has been reported to occur in the case of far advanced stage of a disease or in the case of more than one organ.

---

Figure 1
Abdomen CT shows 9 × 8 cm-sized multiseptated cystic lesion with inner calcification in the spleen.
was already involved in terminal stage and especially in the case of peritoneal metastasis. When one or more organ in the thoracic cavity and abdominal cavity was involved, the rate of splenic metastasis was 43% [12]. But isolated splenic metastasis is rare; only fewer than 25 cases were reported. Some reported hematogenous metastasis to the parenchyma of the spleen [13]. This mean the spleen is the organ of the privilege [11,14,15]. It could be explained by hypothesis of the role of the splenic capsule as physical barrier; the lack of afferent lymphatics in the splenic parenchyma, the acute angle of the origin and the tortuosity of the splenic artery, the rhythmic contractile properties of the spleen, and the immune competence and possible antineoplastic nature of the splenic tissue itself [13]. In this case, solitary splenic parenchymal metastasis from ovarian epithelial tumor was made hematogenously without intraabdominal dissemination.

Among cases of the isolated splenic metastasis, the ovarian cancers make up the most. After Minazawa et al [16] firstly performed splenectomy in the splenic metastasis of ovarian cancer patient, splenectomy, as a therapeutic modality of splenic metastasis, was supported by similar articles and studies [17,18]. Recently, splenectomy was often included in the cytoreductive surgery of the ovarian cancer [2,3,19].

CT scanning and measurement of serum tumor markers, especially CA 125, are helpful for detecting the recurrence and the infrequent splenic metastasis.

We proposed that splenectomy be a proper therapeutic modality for an isolated splenic metastasis, especially parenchymal metastasis, from an ovarian cancer. When isolated splenic recurrence is suspected on the CT

Figure 2
The section reveals papillary hyperplasia of mucinous lining epithelium with stratification and atypism (H&E stain, ×250).
scanning and serum tumor markers, intraabdominal gross findings should be examined meticulously. If only spleen was under suspicion of recurrence, splenectomy would be a proper therapeutic procedure.

**Competing interests**
The author(s) declare that they have no competing interests.

**Authors’ contributions**
YS carried out the literature search and prepared the manuscript. JC Kim, the corresponding author, was the main operator in charge of the case. CK was involved in the operation and the patient active management. Three authors read and approved the final manuscript.

**Acknowledgement**
Written consent for publication of the case was obtained from a relative of a patient.

**References**
1. Marymont JH, Gross S. Patterns of metastatic cancer in the spleen. Am J Clin Pathol 1963, 40:58-66.
2. Nicklin JL, Copeland LJ, O'Toole RV, Lewandowski GS, Vaccarello L, Havenar LP. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1995, 58:244-247.
3. Sonnendecker EW, Guidozi F, Margolius KA. Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1989, 35:301-306.
4. Morris M, Gorschenson DM, Burke TW, Whaton JT, Copeland LJ, Rutledge FN. Splenectomy in gynecologic oncology: Indications, complications and technique. Gynecol Oncol 1991, 43:118-122.
5. Farias-Eisner R, Braly P, Berek JS. Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Gynecol Oncol 1993, 48:338-341.
6. Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN, Wharton JT, Gorschenson DM. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997, 64:13-17.
7. Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol 1999, 72:407-410.
8. Max LD, Strastrak JF, Frable WJ. Solitary splenic metastasis of an adenocarcinoma of the ovaries. Gynecol Obstet Invest 1996, 42:214-216.
9. Hirst AE, Bullock WK. Metastatic carcinoma of the spleen. Am J Med Sci 1952, 223:414-417.
10. Berge T. Splenic metastases Frequencies and patterns. Acta Pathol Microbiol Scand 1974, 82:499-506.
11. Warren S, Davis AH. Studies on tumor metastasis: The metastases of carcinoma to the spleen. Am J Cancer 1934, 21:517-533.
12. Harman JW, Dacorso P. Spread of carcinoma to the spleen: Its relation to generalized carcinomatous spread. Arch Pathol 1948, 45:179-186.
13. Lee SS, Morgenstern L, Phillips EH, Hiss JF, Margulies DR. Splenectomy for splenic metastases: a changing clinical spectrum. Am Surg 2000, 66:837-840.
14. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
15. Morgenstern L, Rosenberg J, Geller SA. Tumors of the spleen. World J Surg 1985, 9:468-476.
16. Minagawa Y, Kanamori Y, Ishihara H, Morishita K, Kigawa J, Ito T, Maeda K, Saito S. Solitary metastatic ovarian carcinoma of the spleen: A case report. Asia Oceania J Obstet Gynecol 1991, 17:45-48.
17. Glezerman M, Yanai-Inbar I, Charuzi I, Katz M, Glasner M, Piura B. Involvement of the spleen in ovarian adenosquamous carcinoma. Gynecol Oncol 1988, 30(1):143-148.
18. Carrington BM, Thomas NB, Johnson RJ. Intrasplic metastases from carcinoma of the ovary. Clin Radiol 1990, 41:418-420.
19. Malfetano JH. Splenectomy for optimal cytoreduction in ovarian cancer. Gynecol Oncol 1986, 24:392-394.

**Pre-publication history**
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/4/96/prepub